|
KMID : 0578320180410080717
|
|
Molecules and Cells
2018 Volume.41 No. 8 p.717 ~ p.723
|
|
|
Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies
|
|
Jung In-Young
Lee Jung-Min
|
|
|
Abstract
|
|
|
|
Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibility to this transformative medicine is highly limited due to the complex process of manufacturing, limited options for target antigens, and insufficient anti-tumor responses against solid tumors. Advances in gene-editing technologies, such as the development of Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9), have provided novel engineering strategies to address these limitations. Development of next-generation CAR-T cells using gene-editing technologies would enhance the therapeutic potential of CAR-T cell treatment for both hematologic and solid tumors. Here we summarize the unmet medical needs of current CAR-T cell therapies and gene-editing strategies to resolve these challenges as well as safety concerns of gene-edited CAR-T therapies.
|
|
|
KEYWORD
|
|
|
CAR-T cell, CRISPR/Cas9, gene editing
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|